ACE-536 is named as a drug or biological intervention in 2 clinical trials in our USA, China, Ireland, UK and India trial registers, 1 of which is recruiting. The lead sponsor is Celgene. Registered phases: Phase 3 and Phase 2. Conditions studied include Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04143724 | Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (ฮฒ)-Thalassemia (ClinicalTrials.gov ↗) Beta-Thalassemia |
Phase 2 | Recruiting |
| NCT04717414 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (ClinicalTrials.gov ↗) Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Myeloproliferative Disorders | 1 |
| Myelofibrosis | 1 |
| Primary Myelofibrosis | 1 |
| Post-Polycythemia Vera Myelofibrosis | 1 |
| Beta-Thalassemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Celgene | 2 |
| Register | ACE-536 trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in China | 2 |
| Clinical trials in Ireland | 1 |
| Clinical trials in UK | 1 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how ACE-536 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ACE-536 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.